Evidence map›Paper›PMID 37289545›Full record

ArticleThe Journal of clinical investigation2023

Phospholipid scramblase-1 regulates innate type 2 inflammation in mouse lungs via CRTH2-dependent mechanisms.

Ashley Hernandez-Gutierrez, Sonoor Majid, Adam Eberle, Ashley Choi, Parand Sorkhdini, Dongqin Yang, Alina Xiaoyu Yang, Carmelissa Norbrun, Chuan Hua He, Chang-Min Lee and 3 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ashley Hernandez-GutierrezDepartment of Molecular Microbiology and Immunology and.
Sonoor MajidDepartment of Molecular Microbiology and Immunology and.
Adam EberleDepartment of Molecular Microbiology and Immunology and.
Ashley ChoiDepartment of Molecular Microbiology and Immunology and.
Parand SorkhdiniDepartment of Molecular Microbiology and Immunology and.
Dongqin YangDepartment of Molecular Microbiology and Immunology and.
Alina Xiaoyu YangDepartment of Molecular Microbiology and Immunology and.
Carmelissa NorbrunDepartment of Molecular Microbiology and Immunology and.
Chuan Hua HeDepartment of Molecular Microbiology and Immunology and.
Chang-Min LeeDepartment of Molecular Microbiology and Immunology and.
Chun Geun LeeDepartment of Molecular Microbiology and Immunology and.
Jack A EliasDepartment of Molecular Microbiology and Immunology and.
Yang ZhouDepartment of Molecular Microbiology and Immunology and.
Brown University · US

Funding

Tracking and Evaluation CoreU54GM115677 · NIGMS · BROWN UNIVERSITY · PI KOGUT, STEPHEN J · 2016 to 2025
$45.0M
Uncoupling of IL-1 beta and VEGF-A Crosstalk Contributes to Impaired Arteriogenesis Response to Ischemia in Chronic Diabetes MellitusP20GM103652 · NIGMS · OCEAN STATE RESEARCH INSTITUTE, INC. · PI CHOUDHARY, GAURAV, HARRINGTON, ELIZABETH O · 2013 to 2022
$21.3M
YKL-40 in Idiopathic Pulmonary Fibrosis and Kidney TransplantationU01HL108638 · NHLBI · YALE UNIVERSITY · PI ELIAS, JACK A · 2011 to 2014
$2.6M
Targeting CHI3L and its receptors in Hermansky-Pudlak Syndrome-associated lung diseaseR01HL146498 · NHLBI · BROWN UNIVERSITY · PI ZHOU, YANG · 2020 to 2024
$2.2M
BRP-39/YKL-40 in Th2 Inflammation and AsthmaR01HL093017 · NHLBI · YALE UNIVERSITY · PI ELIAS, JACK A · 2010 to 2013
$1.6M
Chitinase1 as a Biomarker and Therapeutic Target in Scleroderma Lung DiseaseR01HL115813 · NHLBI · BROWN UNIVERSITY · PI LEE, CHUN GEUN · 2014 to 2017
$1.5M
NHLBI NIH HHS R01 HL093017NHLBI NIH HHS R01 HL115813NHLBI NIH HHS R01 HL146498NHLBI NIH HHS U01 HL108638NIGMS NIH HHS P20 GM103652NIGMS NIH HHS U54 GM115677
6 · The paper itself

Abstract

Exaggerated Type 2 immune responses play critical roles in the pathogenesis of a variety of diseases including asthma, allergy, and pulmonary fibrosis. Recent studies have highlighted the importance of innate type 2 immune responses and innate lymphoid 2 cells (ILC2s) in these disorders. However, the mechanisms that control the development of pulmonary innate type 2 responses (IT2IR) and the recruitment and/or activation of ILC2 cells are poorly understood. In mouse models of pulmonary IT2IR, we demonstrated that phospholipid scramblase-1 (PLSCR1), a type II transmembrane protein that mediates bidirectional and nonspecific translocation of phospholipids between the inner and outer leaflets of the plasma membrane, was a critical regulator of IT2IR in the lung. We further suggested that (a) PLSCR1 bound to and physically interacted with chemoattractant receptor-homologous molecule(CRTH2), which is a G-protein-coupled receptor that is expressed on TH2 cells and on multiple immune cells and is commonly used to identify ILC2 cells, and (b) the effects of PLSCR1 on ILC2 activation and IT2IR were mediated via CRTH2-dependent mechanisms. Overall, our studies demonstrated that PLSCR1 played an essential role in the pathogenesis of ILC2 responses, providing critical insights into biology and disease pathogenesis and identifying targets that can be manipulated in attempts to control IT2IR in chronic diseases such as asthma.

Indexed as

AsthmaImmunity, InnateAnimalsCytokinesInflammationLungLymphocytesMicePhospholipid Transfer ProteinsCytokinesPhospholipid Transfer ProteinsAllergyAsthmaImmunologyInnate immunity

Identifiers

PMID37289545
PMCPMC10378191
OpenAlexW4379879002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.